蜜桃传媒app
Download the D2R Factsheet听听Download the D2R Booklet
About D2R Initiative
Advances in genome (DNA) and transcriptome (RNA) and other 鈥渙mics鈥� technologies have identified the genetic drivers of many human diseases. Yet developing targeted therapeutic interventions, or "precision medicines" through traditional drug development has proven often difficult and costly. RNA therapies have emerged as powerful alternatives that have the potential to target any diseases, including those with seemingly 鈥渦ndruggable鈥� targets, hence improving the health and quality of life for many.
The D2R Initiative aims to rapidly expand the therapeutic arsenal for precision medicine by fulfilling the potential of genomic discovery and capitalizing on the flexibility of RNA therapies to benefit all, including marginalized and medically underserved groups.
Vision
To deliver genomic-based RNA therapies to benefit the health of different populations who are affected by infectious, rare and neglected diseases, or common chronic diseases such as cancer.
Mission
To develop an internationally leading initiative in the discovery and development of genome-guided, RNA-based precision medicines, associated computational tools, along with a clinical accelerator to ensure application of its discoveries for all Canadians and for the world.
Strategic objectives
Enable discovery
D2R will overcome scientific and technical obstacles to realize the potential of genome-guided precision medicine and RNA therapies.
Make an impact
To realize the potential of genomic discovery and capitalize on the flexibility of RNA therapeutics, D2R is implementing an interdisciplinary research strategy to tackle priority disease areas.
Be inclusive
D2R promises to improve knowledge and advance health outcomes for diverse populations globally. Objectives include to engage patient associations and equity deserving groups to guide research and policy recommendations. To successfully implement and deploy these medicines, particularly for underserved populations, D2R will create and analyze diverse socio-genomic datasets, and investigate and address ethical, legal, and societal issues linked to RNA therapeutics. D2R will address societal and policy questions to ensure that the diversity of our populations and health needs are considered.
Engage partners
D2R will be a hub for world-leading 鈥渘ext-generation鈥� drug development in Canada, bringing together pharma and biotech to accelerate regulatory approval of life saving drugs. D2R鈥檚 scope and Canada鈥檚 competitiveness in these areas will be advanced through strong international links with leading biomedical research institutions in Europe, North America, Africa, and Asia.
Champion Indigenous-Led Research Initiatives
D2R is deeply committed to fostering Indigenous leadership within the realms of genomic medicine, RNA therapeutics and health inequities. We prioritize the integration of Indigenous knowledge by actively promoting co-creation and ensuring that all engagements are culturally safe and respectful. This commitment involves building substantial partnerships that support the autonomy and leadership of Indigenous researchers and communities in directing research agendas. Our approach not only respects but relies on Indigenous governance structures and ethics to guide project development, data management, and dissemination of results, ensuring outcomes are beneficial and aligned with the priorities of Indigenous communities.
听
Here is a look at McGill鈥檚 game-changing research and the people behind the science.
